Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
IDEAYA Biosciences
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05987332CT.gov IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | — | Active Not Recruiting | — | — | — |
NCT03070392CT.gov Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | — | Completed | — | — | — |
NCT01974752CT.gov Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) | — | Completed | — | — | — |
NCT01143402CT.gov Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | — | Completed | — | — | — |
NCT01100528CT.gov Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dacarbazine (this asset) | IDEAYA Biosciences | P3 | BB · 66 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Dacarbazine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Melanoma | — | P4 | BBB · 72 |
| Cutaneous Melanoma | — | P3 | BBB · 72 |
| Hodgkins Lymphoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dacarbazine in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dacarbazine-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →